Difference between revisions of "Mogamulizumab (Poteligeo)"
Jump to navigation
Jump to search
(Created page with "=Mechanism of action= Defucosylated anti-cc chemokine receptor 4 (CCR4) antibody =Preliminary results= # Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto ...") |
m |
||
| Line 3: | Line 3: | ||
=Preliminary results= | =Preliminary results= | ||
| + | ==[[T-cell lymphoma]]== | ||
# Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014 Apr 10;32(11):1157-63. Epub 2014 Mar 10. [http://jco.ascopubs.org/content/32/11/1157.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/24616310 PubMed] | # Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014 Apr 10;32(11):1157-63. Epub 2014 Mar 10. [http://jco.ascopubs.org/content/32/11/1157.long link to original article] [http://www.ncbi.nlm.nih.gov/pubmed/24616310 PubMed] | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | |||
| + | [[Category:Immunotherapy]] | ||
| + | [[Category:Antibody medications]] | ||
| + | |||
| + | [[Category:T-cell lymphoma medications]] | ||
[[Category:Investigational]] | [[Category:Investigational]] | ||
| − | |||
Revision as of 14:19, 26 November 2014
Mechanism of action
Defucosylated anti-cc chemokine receptor 4 (CCR4) antibody
Preliminary results
T-cell lymphoma
- Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga S, Tomonaga M, Ueda R. Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-cc chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol. 2014 Apr 10;32(11):1157-63. Epub 2014 Mar 10. link to original article PubMed